{"entity":{"type":"insider","cik":"0001580575","url":"/insider/0001580575","json_url":"/insider/0001580575.json","name":"Baker Bros. Advisors (GP) LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":2200,"n_filings":205,"first":"2013-08-02","last":"2026-07-16","span_basis":"filed_date"},"name_variants":[{"name":"Baker Bros. Advisors (GP) LLC","source":"filing","n_filings":205,"first_seen":"2013-08-02","last_seen":"2026-07-16"}],"transactions":[{"id":6117408,"accession":"0001193125-26-306299","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-306299","line_url":"/filing/0001193125-26-306299","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Celcuity Inc.","issuer_ticker":"CELC","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3100000.0,"shares_display":"3,100,000","price_per_share":102.5,"price_display":"102.50","price_state":"stated","total_value":317750000.0,"total_display":"317,750,000.00","total_whole":"317,750,000","shares_owned_after":4372852.0,"shares_owned_after_display":"4,372,852","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-14","filed_date":"2026-07-16","scope":"insider","n_lines":2},{"id":6177542,"accession":"0001193125-26-242066","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-242066","line_url":"/filing/0001193125-26-242066","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"BeOne Medicines Ltd.","issuer_ticker":"ONC","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10998.0,"shares_display":"10,998","price_per_share":23.820778250591015,"price_display":"23.82","price_state":"stated","total_value":261980.9192,"total_display":"261,980.92","total_whole":"261,981","shares_owned_after":142570.0,"shares_owned_after_display":"142,570","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-22","filed_date":"2026-05-27","scope":"insider","n_lines":4},{"id":5026583,"accession":"0001193125-25-326820","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-326820","line_url":"/filing/0001193125-25-326820","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Kodiak Sciences Inc.","issuer_ticker":"KOD","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2608696.0,"shares_display":"2,608,696","price_per_share":23.0,"price_display":"23.00","price_state":"stated","total_value":60000008.0,"total_display":"60,000,008.00","total_whole":"60,000,008","shares_owned_after":18358772.0,"shares_owned_after_display":"18,358,772","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-18","filed_date":"2025-12-19","scope":"insider","n_lines":2},{"id":4426555,"accession":"0001193125-25-315999","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-315999","line_url":"/filing/0001193125-25-315999","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2005813.0,"shares_display":"2,005,813","price_per_share":86.0,"price_display":"86.00","price_state":"stated","total_value":172499918.0,"total_display":"172,499,918.00","total_whole":"172,499,918","shares_owned_after":7955916.0,"shares_owned_after_display":"7,955,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-11","filed_date":"2025-12-11","scope":"insider","n_lines":2},{"id":4624049,"accession":"0001193125-25-293698","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-293698","line_url":"/filing/0001193125-25-293698","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":28867.0,"shares_display":"28,867","price_per_share":9.070777067239408,"price_display":"9.07","price_state":"stated","total_value":261846.1216,"total_display":"261,846.12","total_whole":"261,846","shares_owned_after":4678310.0,"shares_owned_after_display":"4,678,310","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-20","filed_date":"2025-11-24","scope":"insider","n_lines":4},{"id":5025615,"accession":"0001193125-25-278038","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001193125-25-278038","line_url":"/filing/0001193125-25-278038","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100736.0,"shares_display":"100,736","price_per_share":7.759271489834815,"price_display":"7.76","price_state":"stated","total_value":781637.9728,"total_display":"781,637.97","total_whole":"781,638","shares_owned_after":4653430.0,"shares_owned_after_display":"4,653,430","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-12","filed_date":"2025-11-12","scope":"insider","n_lines":4},{"id":5025598,"accession":"0001193125-25-278038","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193125-25-278038","line_url":"/filing/0001193125-25-278038","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":46434.0,"shares_display":"46,434","price_per_share":7.498664922255244,"price_display":"7.50","price_state":"stated","total_value":348193.007,"total_display":"348,193.01","total_whole":"348,193","shares_owned_after":4572549.0,"shares_owned_after_display":"4,572,549","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-11","filed_date":"2025-11-12","scope":"insider","n_lines":4},{"id":5025581,"accession":"0001193125-25-278038","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-278038","line_url":"/filing/0001193125-25-278038","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30874.0,"shares_display":"30,874","price_per_share":7.214993055645527,"price_display":"7.21","price_state":"stated","total_value":222755.6956,"total_display":"222,755.70","total_whole":"222,756","shares_owned_after":4527022.0,"shares_owned_after_display":"4,527,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-10","filed_date":"2025-11-12","scope":"insider","n_lines":4},{"id":4135306,"accession":"0001193125-25-228536","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-228536","line_url":"/filing/0001193125-25-228536","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"KALA BIO, Inc.","issuer_ticker":"KALA","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":513607.0,"shares_display":"513,607","price_per_share":1.3838,"price_display":"1.38","price_state":"stated","total_value":710729.3666,"total_display":"710,729.37","total_whole":"710,729","shares_owned_after":425006.0,"shares_owned_after_display":"425,006","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-01","filed_date":"2025-10-02","scope":"insider","n_lines":2},{"id":4135302,"accession":"0001193125-25-228536","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-228536","line_url":"/filing/0001193125-25-228536","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"KALA BIO, Inc.","issuer_ticker":"KALA","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":216801.0,"shares_display":"216,801","price_per_share":1.5959,"price_display":"1.60","price_state":"stated","total_value":345992.7159,"total_display":"345,992.72","total_whole":"345,993","shares_owned_after":887973.0,"shares_owned_after_display":"887,973","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-30","filed_date":"2025-10-02","scope":"insider","n_lines":2},{"id":4793359,"accession":"0000950170-25-113977","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-113977","line_url":"/filing/0000950170-25-113977","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Celcuity Inc.","issuer_ticker":"CELC","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC","owner_display_name":"BAKER BROS. ADVISORS LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":170100.0,"shares_display":"170,100","price_per_share":56.268774603174606,"price_display":"56.27","price_state":"stated","total_value":9571318.56,"total_display":"9,571,318.56","total_whole":"9,571,319","shares_owned_after":7207272.0,"shares_owned_after_display":"7,207,272","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-10","scope":"insider","n_lines":4},{"id":4793249,"accession":"0000950170-25-110502","txn_seq":26,"anchor":"line-26","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-26","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13545.0,"shares_display":"13,545","price_per_share":385.0573,"price_display":"385.06","price_state":"stated","total_value":5215601.1285,"total_display":"5,215,601.13","total_whole":"5,215,601","shares_owned_after":1931293.0,"shares_owned_after_display":"1,931,293","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793245,"accession":"0000950170-25-110502","txn_seq":25,"anchor":"line-25","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-25","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9477.0,"shares_display":"9,477","price_per_share":381.1216,"price_display":"381.12","price_state":"stated","total_value":3611889.4032,"total_display":"3,611,889.40","total_whole":"3,611,889","shares_owned_after":1909725.0,"shares_owned_after_display":"1,909,725","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793241,"accession":"0000950170-25-110502","txn_seq":24,"anchor":"line-24","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-24","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9362.0,"shares_display":"9,362","price_per_share":392.2429,"price_display":"392.24","price_state":"stated","total_value":3672178.0298,"total_display":"3,672,178.03","total_whole":"3,672,178","shares_owned_after":1947968.0,"shares_owned_after_display":"1,947,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793237,"accession":"0000950170-25-110502","txn_seq":23,"anchor":"line-23","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-23","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5209.0,"shares_display":"5,209","price_per_share":380.4365,"price_display":"380.44","price_state":"stated","total_value":1981693.7285,"total_display":"1,981,693.73","total_whole":"1,981,694","shares_owned_after":1898329.0,"shares_owned_after_display":"1,898,329","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793233,"accession":"0000950170-25-110502","txn_seq":22,"anchor":"line-22","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-22","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4441.0,"shares_display":"4,441","price_per_share":387.068,"price_display":"387.07","price_state":"stated","total_value":1718968.988,"total_display":"1,718,968.99","total_whole":"1,718,969","shares_owned_after":1935734.0,"shares_owned_after_display":"1,935,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793229,"accession":"0000950170-25-110502","txn_seq":21,"anchor":"line-21","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-21","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4049.0,"shares_display":"4,049","price_per_share":383.7872,"price_display":"383.79","price_state":"stated","total_value":1553954.3728,"total_display":"1,553,954.37","total_whole":"1,553,954","shares_owned_after":1917748.0,"shares_owned_after_display":"1,917,748","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793225,"accession":"0000950170-25-110502","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-20","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2838.0,"shares_display":"2,838","price_per_share":382.8213,"price_display":"382.82","price_state":"stated","total_value":1086446.8494,"total_display":"1,086,446.85","total_whole":"1,086,447","shares_owned_after":1913699.0,"shares_owned_after_display":"1,913,699","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793221,"accession":"0000950170-25-110502","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-19","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2506.0,"shares_display":"2,506","price_per_share":389.8878,"price_display":"389.89","price_state":"stated","total_value":977058.8268,"total_display":"977,058.83","total_whole":"977,059","shares_owned_after":1938606.0,"shares_owned_after_display":"1,938,606","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793217,"accession":"0000950170-25-110502","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-18","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1919.0,"shares_display":"1,919","price_per_share":380.78,"price_display":"380.78","price_state":"stated","total_value":730716.82,"total_display":"730,716.82","total_whole":"730,717","shares_owned_after":1900248.0,"shares_owned_after_display":"1,900,248","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793213,"accession":"0000950170-25-110502","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-17","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1248.0,"shares_display":"1,248","price_per_share":385.0573,"price_display":"385.06","price_state":"stated","total_value":480551.5104,"total_display":"480,551.51","total_whole":"480,552","shares_owned_after":201277.0,"shares_owned_after_display":"201,277","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793209,"accession":"0000950170-25-110502","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-16","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1136.0,"shares_display":"1,136","price_per_share":382.2891,"price_display":"382.29","price_state":"stated","total_value":434280.4176,"total_display":"434,280.42","total_whole":"434,280","shares_owned_after":1910861.0,"shares_owned_after_display":"1,910,861","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793205,"accession":"0000950170-25-110502","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-15","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":873.0,"shares_display":"873","price_per_share":381.1216,"price_display":"381.12","price_state":"stated","total_value":332719.1568,"total_display":"332,719.16","total_whole":"332,719","shares_owned_after":199289.0,"shares_owned_after_display":"199,289","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793202,"accession":"0000950170-25-110502","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-14","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":862.0,"shares_display":"862","price_per_share":392.2429,"price_display":"392.24","price_state":"stated","total_value":338113.3798,"total_display":"338,113.38","total_whole":"338,113","shares_owned_after":202813.0,"shares_owned_after_display":"202,813","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793199,"accession":"0000950170-25-110502","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-13","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":480.0,"shares_display":"480","price_per_share":380.4365,"price_display":"380.44","price_state":"stated","total_value":182609.52,"total_display":"182,609.52","total_whole":"182,610","shares_owned_after":198240.0,"shares_owned_after_display":"198,240","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793195,"accession":"0000950170-25-110502","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-12","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":409.0,"shares_display":"409","price_per_share":387.068,"price_display":"387.07","price_state":"stated","total_value":158310.812,"total_display":"158,310.81","total_whole":"158,311","shares_owned_after":201686.0,"shares_owned_after_display":"201,686","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"},{"id":4793191,"accession":"0000950170-25-110502","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502#line-11","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":373.0,"shares_display":"373","price_per_share":383.7872,"price_display":"383.79","price_state":"stated","total_value":143152.6256,"total_display":"143,152.63","total_whole":"143,153","shares_owned_after":200029.0,"shares_owned_after_display":"200,029","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider"}],"collapsed":true,"next_cursor":"2025-08-20|4793191","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001603454","name":"Celcuity Inc.","url":"/issuer/0001603454","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2025-09-10","last_seen":"2026-07-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001651308","name":"BeOne Medicines Ltd.","url":"/issuer/0001651308","role":"Director, Ten percent owner","n_filings":11,"first_seen":"2016-02-09","last_seen":"2026-05-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001468748","name":"Kodiak Sciences Inc.","url":"/issuer/0001468748","role":"Director, Ten percent owner","n_filings":22,"first_seen":"2018-10-11","last_seen":"2025-12-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2024-08-22","last_seen":"2025-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001689375","name":"Entrada Therapeutics, Inc.","url":"/issuer/0001689375","role":"Ten percent owner","n_filings":5,"first_seen":"2022-05-18","last_seen":"2025-11-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001479419","name":"KALA BIO, Inc.","url":"/issuer/0001479419","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2024-12-31","last_seen":"2025-10-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001157601","name":"MADRIGAL PHARMACEUTICALS, INC.","url":"/issuer/0001157601","role":"Director","n_filings":8,"first_seen":"2023-11-15","last_seen":"2025-08-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001671927","name":"Immunocore Holdings plc","url":"/issuer/0001671927","role":"Director","n_filings":1,"first_seen":"2025-03-19","last_seen":"2025-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001761612","name":"BICYCLE THERAPEUTICS PLC","url":"/issuer/0001761612","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2024-12-17","last_seen":"2024-12-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001496323","name":"IGM Biosciences, Inc.","url":"/issuer/0001496323","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2019-09-20","last_seen":"2024-03-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001532346","name":"Atreca, Inc.","url":"/issuer/0001532346","role":"Other","n_filings":1,"first_seen":"2023-10-23","last_seen":"2023-10-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001404644","name":"Neoleukin Therapeutics, Inc.","url":"/issuer/0001404644","role":"Director, Ten percent owner","n_filings":12,"first_seen":"2015-09-11","last_seen":"2023-08-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001070494","name":"ACADIA PHARMACEUTICALS INC","url":"/issuer/0001070494","role":"Director, Ten percent owner","n_filings":10,"first_seen":"2014-03-07","last_seen":"2023-05-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001783328","name":"TScan Therapeutics, Inc.","url":"/issuer/0001783328","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-07-22","last_seen":"2022-05-12"},{"type":"issuer","type_label":"ISSUER","cik":"0000879169","name":"INCYTE CORP","url":"/issuer/0000879169","role":"Director, Ten percent owner","n_filings":10,"first_seen":"2016-02-16","last_seen":"2022-03-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001060736","name":"Seagen Inc.","url":"/issuer/0001060736","role":"Director, Ten percent owner","n_filings":38,"first_seen":"2013-12-05","last_seen":"2021-12-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001584751","name":"Talis Biomedical Corp","url":"/issuer/0001584751","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-02-19","last_seen":"2021-11-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001678660","name":"Prelude Therapeutics Inc","url":"/issuer/0001678660","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2020-09-30","last_seen":"2020-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0000899866","name":"ALEXION PHARMACEUTICALS, INC.","url":"/issuer/0000899866","role":"Director","n_filings":5,"first_seen":"2017-06-16","last_seen":"2020-03-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001760542","name":"HOOKIPA Pharma Inc.","url":"/issuer/0001760542","role":"Other","n_filings":1,"first_seen":"2019-04-23","last_seen":"2019-04-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001131324","name":"GENOMIC HEALTH INC","url":"/issuer/0001131324","role":"Director, Ten percent owner","n_filings":35,"first_seen":"2016-08-15","last_seen":"2019-04-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001730430","name":"Kiniksa Pharmaceuticals, Ltd.","url":"/issuer/0001730430","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2018-05-31","last_seen":"2018-05-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001501134","name":"Invitae Corp","url":"/issuer/0001501134","role":"Ten percent owner","n_filings":2,"first_seen":"2016-11-18","last_seen":"2018-03-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001358403","name":"BELLICUM PHARMACEUTICALS, INC","url":"/issuer/0001358403","role":"Ten percent owner","n_filings":2,"first_seen":"2017-03-28","last_seen":"2018-01-19"},{"type":"issuer","type_label":"ISSUER","cik":"0000861838","name":"IDERA PHARMACEUTICALS, INC.","url":"/issuer/0000861838","role":"Director","n_filings":3,"first_seen":"2015-02-17","last_seen":"2017-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001649904","name":"RHYTHM PHARMACEUTICALS, INC.","url":"/issuer/0001649904","role":"Other","n_filings":1,"first_seen":"2017-10-06","last_seen":"2017-10-06"},{"type":"issuer","type_label":"ISSUER","cik":"0000882796","name":"BIOCRYST PHARMACEUTICALS INC","url":"/issuer/0000882796","role":"Ten percent owner","n_filings":7,"first_seen":"2013-08-02","last_seen":"2016-08-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001576263","name":"Mirati Therapeutics, Inc.","url":"/issuer/0001576263","role":"Ten percent owner","n_filings":4,"first_seen":"2013-10-28","last_seen":"2016-06-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Other","n_filings":1,"first_seen":"2016-05-11","last_seen":"2016-05-11"},{"type":"issuer","type_label":"ISSUER","cik":"0000791908","name":"XOMA Corp","url":"/issuer/0000791908","role":"Director, Ten percent owner, Other","n_filings":8,"first_seen":"2013-08-21","last_seen":"2015-07-23"},{"type":"issuer","type_label":"ISSUER","cik":"0000911326","name":"SYNAGEVA BIOPHARMA CORP","url":"/issuer/0000911326","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2015-01-09","last_seen":"2015-01-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001580575","retrieved_at":"2026-08-26T09:53:30+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}